Cherry (C3RY) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
4 Feb, 2026Financial performance and restructuring
FY 2025 revenue reached €94.3m, down 15% year-over-year, mainly due to divestment and lower demand in Components, while Peripherals showed increased momentum.
Adjusted EBITDA for FY 2025 was -€9.8m, heavily impacted by restructuring, impairments, and legacy costs, though Q4 EBITDA momentum turned positive.
Cash burn was drastically reduced, with cash on hand at €7.5m and equity ratio at 43.2% as of September 2025.
Inventory levels were reduced by over €5m quarter-over-quarter, with active office SKUs cut by about 40% since January 2025.
Group revenue and EBITDA declined across all divisions for 9M 2025, but Peripherals and Digital Health & Solutions saw Q3 revenue growth year-over-year.
Strategic milestones and operational updates
Strategic realignment confirmed at AGM, with shareholder approval for transformation and expansion of the Management Board.
TI-Messenger provider approval received, enabling new digital health communication capabilities.
Auerbach site reshaped as a central development, logistics, and services hub, with logistics operations consolidated and external partnerships reduced.
Integrated product and technology development established, with a focus on Peripherals and Digital Health & Solutions and a defined technology roadmap for 2026 and beyond.
Outlook and transformation initiatives
Interim CEO Rogier Volmer appointed, bringing turnaround and transformation experience from previous roles.
Structured M&A process initiated to divest either Peripherals or Digital Health, aiming to strengthen financial flexibility and complete a transaction in H1 2026.
Digital Health & Solutions targets recurring SaaS revenue growth, with TI-M Pro launched and a shift from hardware to software revenue streams.
Peripherals business streamlined, with SKU reduction, talent acquisition, and increased focus on APAC and EMEA regions.
Major shareholder committed up to €5.7m, legal entities reduced for efficiency, and liquidity management prioritized.
Latest events from Cherry
- 2025 revenue fell 15% to €94.3M, with cost cuts, margin recovery, and segment review ongoing.C3RY
Q4 20255 Mar 2026 - 2024 guidance targets €140m–€150m revenue and a 7–8% EBITDA margin, signaling a strong turnaround.C3RY
Investor presentation4 Feb 2026 - Revenue and EBITDA fell short, triggering cost cuts and a revised €120m 2024 outlook.C3RY
Investor presentation4 Feb 2026 - Streamlined for margin-driven growth, with €120M 2024 revenue forecast and €3.5M cost savings.C3RY
Investor presentation4 Feb 2026 - Digital Health & Solutions growth and cost controls support outlook despite margin pressure.C3RY
Q2 20243 Feb 2026 - Q3 2024 results missed expectations, triggering restructuring and a cut in full-year guidance.C3RY
Q3 2024 TU19 Jan 2026 - Revenue and margins fell, but Q4 free cash flow rose as restructuring targets 2025 recovery.C3RY
Q4 2024 TU26 Dec 2025 - Restructuring and SaaS focus aim to restore profitability and drive growth in 2025.C3RY
Analyst Day 202525 Nov 2025 - 9M 2025 revenue down 16%, Q3 up 9.3% YoY; net loss widens amid restructuring.C3RY
Q3 2025 TU17 Nov 2025